Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Federal Trade Commission/Eye Research Associates.

This article was originally published in The Gray Sheet

Executive Summary

Consent agreement proposed by FTC in a Feb. 25 Federal Register notice would settle claims that ERA made "false, unsubstantiated" and "deceptive" claims in direct-to-consumer print advertisements and videotapes in promoting its "Controlled Kerato Reformation orthokeratology (CKR Ortho-K) service. Ortho-K is a non-surgical process in which a patient wears, usually while asleep, custom-designed extended-wear contact lenses that reshape the corneal curvature of the eye. FTC proposes that the company remove from advertisements certain claims, including one stating that the procedure corrects myopia and astigmatism, "thereby permanently eliminating the need for eyewear." FTC is seeking public comment on the proposed consent order by April 27. FDA's Ophthalmology Devices Panel raised concern with Ortho-K at a Feb. 12 meeting; the agency is developing guidance for manufacturers of Ortho-K lenses following a recent FDA decision to require approval of a premarket approval application ("The Gray Sheet" Feb. 23, p. 9)...

You may also be interested in...

GT Medical Technologies Raised $16M In Funding To Expand Brain Tumor Therapy

The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts